Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Neoplasms 39Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 31Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Carcinoma 10Stomach Neoplasms 8Neuroendocrine Tumors 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Adenoma, Islet Cell 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Clear-cell metastatic renal cell carcinoma 6

Interventions

Vorinostat 2pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumour × Sunitinib × Clear all
NCT01286896 2025-07-10

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

The Netherlands Cancer Institute

Phase 1 Completed
43 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡